Literature DB >> 23488586

Evaluation scale development, reliability for sitting and standing from the chair for Duchenne muscular dystrophy.

Michele Emy Hukuda1, Renata Escorcio, Lilian Aparecida Yoshimura Fernandes, Eduardo Vital de Carvalho, Fátima Aparecida Caromano.   

Abstract

The authors aimed to (a) develop a scale to evaluate non-wheelchair-dependent children with Duchenne muscular dystrophy (DMD) while sitting and standing from the chair, (b) test its reliability, and (c) correlate the scores of this scale with the time, the age and the Vignos. Thirty DMD boys performed sit-to-stand and stand-to-sit from the chair 4 times. Scale development was based on a previous movement characterization in healthy children and in DMD children and on suggestions by physical therapists with expertise in DMD. The final version of the scale was submitted to the analysis of reliability. The sitting evaluation consists of phases: flexion, contact of the hip with the chair, extension. The standing evaluation comprehends the phases: flexion; transference; extension. Sitting and standing phases presented an excellent reliability (intraclass correlation coefficient [ICC] ≥ 0.91) and a good reproducibility (ICC ≥ 0.89). The scores generated by sitting on the chair correlated to the time taken to perform the tasks (r = .69) and to the age of the patient (r = .44) and the score of standing from the chair also correlated to the time of performance (r = .66). The sit-to-stand functional evaluation scale DMD is a reliable assessment tool that allows the description and quantification of the functional performance of DMD children.

Entities:  

Mesh:

Year:  2013        PMID: 23488586     DOI: 10.1080/00222895.2012.760513

Source DB:  PubMed          Journal:  J Mot Behav        ISSN: 0022-2895            Impact factor:   1.328


  3 in total

1.  Relationship between the climbing up and climbing down stairs domain scores on the FES-DMD, the score on the Vignos Scale, age and timed performance of functional activities in boys with Duchenne muscular dystrophy.

Authors:  Lilian A Y Fernandes; Fátima A Caromano; Silvana M B Assis; Michele E Hukuda; Mariana C Voos; Eduardo V Carvalho
Journal:  Braz J Phys Ther       Date:  2014 Nov-Dec       Impact factor: 3.377

2.  Responsiveness of the domain climbing up and going down stairs of the Functional Evaluation scale for Duchenne Muscular Dystrophy: a one-year follow-up.

Authors:  Priscila S Albuquerque; Mariana C Voos; Mariene S Simões; Joyce Martini; Carlos B M Monteiro; Fatima A Caromano
Journal:  Braz J Phys Ther       Date:  2016-06-16       Impact factor: 3.377

3.  Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.

Authors:  Samantha LoRusso; Nicholas E Johnson; Michael P McDermott; Katy Eichinger; Russell J Butterfield; Elena Carraro; Kiley Higgs; Leann Lewis; Karlien Mul; Sabrina Sacconi; Valeria A Sansone; Perry Shieh; Baziel van Engelen; Kathryn Wagner; Leo Wang; Jeffrey M Statland; Rabi Tawil
Journal:  BMC Neurol       Date:  2019-09-10       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.